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New Positive Inotropic Agents 
Syed M. Jafri, MD,* and James A. Bristol, PhD^ 
Current therapy for heart failure remains inadequate. New positive inotropic agents that augment 
myocardial contractility have been introduced. The positive inotropic effects ofthese nonglycoside, 
nonsympathomimetic agents are due, at least in part, to inhibition of cardiac phosphodiesterase 
activity and hence to an increase in myocardial cyclic AMP levels. These agents also have vasodilator 
properties through their effects on the enzyme phosphodiesterase in the vascular smooth muscle. 
Recent developments in the preclinical pharmacology, mechanism of action, and clinical experience 
with these new inotrope vasodilators are presented in this review. The role these drugs will play in 
revising our therapeutic strategy in congestive heart failure remains to be defined. (Henry Ford H osp 
MedJ 1986;34:188-92) 
Current therapy for heart failure is aimed at improving myocardial contractility by reducing volume overload or 
systemic vascular resistance. Digitalis glycosides and sym-
pathomimetic drugs have long been used to improve the contrac-
tile state of the myocardium. The efficacy of chronic digitalis 
therapy in patients with heart failure and sinus rhythm has re-
cendy been challenged (1), and sympathomimetic agents are 
limited by their chronotropic side-effects and their need for in-
travenous administration, 
The requirements of a clinically useful inotropic agent have 
been summarized in a recent review by Braunwald and Colucci 
(2). An ideal agent should produce hemodynamic improvement 
(both at rest and with exercise), have persistent clinical and he-
modynamic effects, be well tolerated and relatively free of side-
effects, and prolong survival. No such agent cunently exists. 
Several "new" positive inotropic agents are undergoing trials, 
including a new class of nonglycoside, nonsympathomimetic 
dmgs. 
Most inotropic agents stimulate myocardial contractility by 
either inhibition of Na + /K+ ATPase, activation of membrane-
bound adenylcyclase, or inhibition of cyclic AMP phos-
phodiesterase (3). Recently, a new class of dmgs which increase 
calcium sensitivity of the myofilaments partly by increasing the 
affinity of troponin to calcium has been described (4). This re-
view focuses primarily on one class of these newer inotropic 
agents that have phosphodiesterase inhibitory properties and po-
tential as therapeutic agents in the management of patients with 
heart failure. 
19,205); and 4,5-dihydro-3(2H)-pyridazinones of which im-
azodan (CI-914) and CI-930 are the most prominent examples. 
Thorough characterizadon of preclinical pharmacology includ-
ing positive inotropic efficacy and studies designed to elucidate 
the mechanism of action have been reported for these agents and 
are summarized here briefly. 
Amrinone and milrinone 
The preclinical pharmacology of amrinone and milrinone 
has been studied extensively (5,6). The two agents have sim-
ilar properties, with milrinone characterized as 10 to 30 dmes 
more potent than amrinone. The cardiovascular responses to 
amrinone have been evaluated in vitro and in vivo in dogs, cats, 
monkeys, and man. In vitro treatment of isolated cat atria 
and papillary muscles with amrinone (3 to 1000 p-g/mL) pro-
duces dose-dependent increases in atrial and papillary muscle-
developed tension (5). Intravenous administration of 1 to 10 
mg/kg of amrinone to anesthetized dogs produces dose-related 
increases in contractility (dP/dtmax), slight increases in heart 
rate, and slight decreases in blood pressure (5). Oral doses of 
amrinone to conscious dogs (1 to 10 mg/kg) produce an increase 
in cardiac contractile force with a long duration of acdon. Simi-
larly, intravenous administration of 0.01 to 0.1 mg/kg of 
milrinone to anesthetized dogs produces significant changes in 
contractility (23% to 87%), whereas heart rate and blood pres-
sure are relatively unaffected (6). Oral doses of milrinone (0.1 to 
1.0 mg/kg) to conscious dogs produce a dose-related increase in 
contractility. 
Preclinical Evaluation of Positive Inotropic 
Efficacy of Phosphodiesterase Inhibitors 
The newer agents being developed for treatment of heart 
failure generally fall into three main classes of chemical stmc-
ture: 2(lH)-pyridones, also referred to as bipyridines, which 
include amrinone and milrinone; 2H-imidazol-2-ones which 
include enoximone (MDL 17,043) and piroximone (MDL 
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Table 1 
Positive Inotropic Effects of New Agents for 
Congestive Heart Failure in Conscious Dogs 
Compound (Reference) 
Amrinone ( I I ) 
Milrinone (11) 
Enoximone (7) 
Piroximone (8) 
Imazodan (11) 
CI-930 ( I I ) 
Dose (mg/kg) 
10.0 
1.0 
10.0 
3.0 
1.0 
0.1 
% Increase Contractility 
45 
45 
49 
54 
40 
42 
Table 2 
Inhibition of Guinea Pig Cardiac Phosphodiesterase by 
New Cardiotonic Agents: Theophylline and Papaverine (14) 
IC50 (^jtmoI/L) 
PDEI PDE II PDE III 
Agent cAMP cGMP cAMP cGMP cAMP 
Amrinone >1000 >1000 720 580 46 
Milrinone 310 340 22U 200 2.5 
Enoximone >1000 >I0OO 860 450 14 
Imazodan >I000 >I0OO 750 530 8.2 
CI-930 820 >IOOO 400 360 2.9 
Papaverine 24 27 6.0 5.1 3.8 
Theophylline 230 310 210 170 340 
Enoximone and piroximone 
The in vivo and in vitro pharmacology for enoximone and pir-
oximone have been extensively evaluated (7,8). In the anesthe-
tized dog, enoximone (7) and piroximone (8) (0.1 to 10 mg/kg) 
result in a dose-related positive inotropic response accompanied 
by a minor increase in heart rate and a minor decrease in blood 
pressure. These hemodynamic changes were not altered by 
alpha or beta blockade (9,10). Both compounds lead to a 
vasodilatory response in the canine pump-perfused hindlimb 
preparation. This acdon was not attenuated by alpha, beta, cho-
linergic, or histaminergic blockade, thus indicating that these 
compounds produce vasorelaxation by a direct mechanism 
(9,10). Oral administradon of enoximone (7) and piroximone (8) 
to conscious dogs produces a dose-related increase in contrac-
tility, with piroximone being approximately three times as po-
tent as enoximone (Table I). 
Imazodan (CI-914) and CI-930 
Studies on imazodan (11-14) and CI-930 (11) have been re-
ported. Imazodan has a dose-related increase in positive ino-
tropic activity in excised guinea pig atrial and rabbit papillary 
muscle preparations. In anesthetized dogs, imazodan (0.001 to 
1.0 mg/kg intravenously) increases myocardial contractility of 
10% to 150% and decreases aortic blood pressure up to 31%. 
Minimal heart rate changes occuned relative to the positive ino-
tropic responses. The positive inotropic responses were not 
blocked by propranolol. Forelimb perfusion studies in the anes-
thetized dog showed that imazodan also produces a direct pe-
ripheral vasodilator action. CI-930 has similar actions to those 
of imazodan with an approximate fivefold to tenfold increase 
in potency. Table I describes the relative oral potencies of 
amrinone, milrinone, enoximone, piroximone, imazodan, and 
CI-930 in the conscious dog (7,8,11). As evident from these 
data, CI-930 is the most potent of these agents. 
Mechanism of action 
Since the pioneering work of Sutherland and Rail (15), who 
first described the role of cyclic AMP as the "second mes-
senger" which mediates the response of cells to hormones and 
neurotransmitters, research into many aspects of cyclic nu-
cleotide metabolism has expanded significantly. Regarding 
potential biochemical mechanisms to augment myocardial con-
tractility, phosphodiesterase inhibition remains an adractive 
mechanism. Inhibition of cAMP phosphodiesterase within the 
myocardial cell and the consequent increase in intracellular 
cAMP serve to open the calcium slow channel. The increased 
intracellular concentration of calcium entering from the slow 
channel causes the release of additional calcium stored in the 
sarcoplasmic reticulum, which in tum initiates contraction via 
interaction with the contractile protein, troponin C. 
Recently, several different molecular forms (isozymes) of 
phosphodiesterase have been separated from tissues of several 
species and characterized kinetically (16). In cardiac tissue iso-
lated from guinea pigs, three molecular forms of phos-
phodiesterase exist. 
Classical inhibitors of phosphodiesterase (PDE), ie, 
theophylline, isobutylmethylxanthine (IBMX), and papaver-
ine, inhibit nonselecdvely all three forms of PDE. Of consider-
able interest and significance was the discovery that the new car-
diotonic agents described in this review inhibit selectively the 
cyclic AMP specific form (PDE III) relative to their effects on 
PDE 1 and 11. The effects of several cardiotonics on inhibition of 
cardiac PDE 111 are compared in Table 2 (17). 
By applying a linear regression analysis, an excellent conela-
tion between inhibition of PDE III in vitro and positive inotropic 
activity in vivo across several stmctural classes was identified. 
This conelation strongly suggests that inhibition of cardiac PDE 
111 represents a principal component of the positive inotropic ac-
tion of these classes of compounds (11). Furthermore, all of the 
newer agents described possess vascular relaxant effects which 
may be associated with inhibition of one of the molecular forms 
of PDE present in vascular tissue (17). 
Clinical Experience with 
Phosphodiesterase Inhibitors 
Amrinone and milrinone 
Amrinone, a bipyridine derivative, the prototype of this 
generation of inotropic agents, has recently been approved for 
intravenous use in patients with congestive heart failure. Both 
intravenous and oral forms of the dmg have been shown to im-
prove hemodynamics and myocardial energetics at rest and with 
exercise (18,19). Parenteral amrinone has hemodynamic effects 
similar to dobutamine in patients with congestive heart failure 
(20). While the hemodynamic effects are sustained during 
amrinone infusion, tachyphylaxis seems to occur after eight to 
24 hours of dobutamine infusion. Comparison of dobutamine. 
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dopamine, and amrinone showed that amrinone caused less 
chronotropic response than dopamine (21). 
The inidal intravenous dose of amrinone is 0.5 to 1.5 mg/kg, 
given as a bolus, followed by an infusion of between 5 to 10 
mg/kg/min, titrated to the hemodynamic response. The onset of 
action is rapid, occuning within ten minutes; however, its half-
life is three to six hours which may be a disadvantage in some 
clinical settings of acute heart failure. Potential side-effects in-
clude hypotension, reversible thrombocytopenia, fever, gas-
trointestinal intolerance, and hepatotoxicity (22). The initial en-
thusiasm for the use of oral amrinone for long-term therapy has 
diminished because the results of double-blind, placebo-con-
trolled studies failed to show significant benefits in exercise ca-
pacity or cardiac function (23,24). 
Milrinone is another bipyridine derivative, with ten to 30 
times the potency of amrinone. Several studies have demon-
strated its beneficial hemodynamic and clinical effects (25). 
Milrinone is better tolerated than amrinone and does not have the 
hematopoietic side-effects. Since it is largely excreted through 
the kidneys, milrinone should be used with caution in patients 
with renal dysfunction. Bairn et al (26) have reported their 
experience of long-term therapy with milrinone in 100 patients. 
Side-effects leading to drug withdrawal including headache, 
muscular weakness, insomnia, and increased ventricular ar-
rhythmias occurred in only 4% of the patients. The drug was 
well tolerated with hemodynamic and clinical improvement; 
however, the mortality rate was 63% after one year of therapy. 
Advanced funcdonal class, impaired renal function, reduced 
ejection fraction, and the presence of nonsustained ventricular 
tachycardia on 24 hr holler monitoring were some ofthe predic-
tors for early mortality. In a study of 20 patients on chronic 
milrinone therapy. Holmes et al (27) noted increased complex 
ventricular anhythmias in 40% of the patients. Further studies 
comparing placebo to milrinone are needed to characterize the 
utility of this dmg. 
Enoximone (MDL 17,043) and piroximone (MDL 19,205) 
MDL 17,043 (enoximone) is an imidazole derivadve with 
similar hemodynamic effects to those of amrinone and 
milrinone (28). The hemodynamic effect of intravenous MDL 
17,043 in patients is comparable to dobutamine except that 
dobutamine has a slightly higher chronotropic effect (29). Oral 
MDL 17,043 is rapidly absorbed with an elimination half-life of 
about 20 hours. The dmg is well tolerated during follow-up, and 
side-effects include gastrointestinal distress, headache, 
agranulocytosis, ventricular ectopy, and abnormal liver function 
tests (28). No improvement in survival was demonstrated in pa-
tients treated with this dmg despite the acute hemodynamic ben-
efit and symptom palliation. 
Piroximone (MDL 19,205) also shows favorable hemo-
dynamic effects when administered acutely (30). Petein et al 
(31) noted that despite the acute hemodynamic effects and short-
term clinical benefit, long-term administration of oral MDL 
19,205 was not effecdve in symptom palliation. The apparent 
lack of favorable long-term effect may be related to the patient 
population or dosage used or may reflect the general use of these 
"new" inotropic agents. 
Imazodan (CI-914) and CI-930 
We have recendy reported the hemodynamic effects of a new 
type 111 phosphodiesterase inhibitor, CI-914, in 13 patients 
with severe congestive heart failure (32). CI-914 is a dihydro-
pyridazinone derivative and in vitro has ten times the potency of 
amrinone (33). It shows only slight stimulation of calcium re-
lease and has no direct effect on sarcoplasmic reticulum, mito-
chondrial function, adenylcyclase, or on NA + /K +ATPase ac-
tivity (33). 
An increase in cardiac index of 26% (P < 0.01), a decrease in 
pulmonary wedge pressure of 21% (P < 0.001), a right atrial 
pressure of 30% (P < 0.02), and systemic vascular resistance of 
23% (P < 0.02) occuned following intravenous CI-914 admin-
istration without significant changes in heart rate, mean blood 
pressure, and pulmonary vascular resistance. Similar changes 
were noted with oral administration of the drug. Peak plasma 
concentration after oral dosage occuned 2.3 ± 2.2 hours after 
ingestion; however, the elimination of this drug appears to be 
nonlinear. The hemodynamic effects of the dmg were sustained 
ten to 12 hours after oral administration (Figure) and appear to 
be related to the combined effect of the dmg as well as its active 
N-acetyl metabolite (17). 
Seven ofthe 13 patients who received long-term therapy for 12 
weeks or more showed improvement in functional class and ex-
ercise capacity, although no significant change in left ventricular 
ejection fraction was seen. Three of these patients remain on 
therapy after 20 months and have had improvement in symp-
toms. The drug was well tolerated without gastrointestinal, 
hematopoietic, and hepatic side-effects. One patient developed 
symptomatic ventricular tachycardia while on the dmg and was 
treated with antianhythmic agents. Although the CI-914 agent 
has some promising characteristics as an inotrope, further stud-
ies are required to elucidate the exact mechanism of action and 
efficacy. 
CI-930 is also a dihydro-pyridazinone derivative, a struc-
tural analogue of CI-914, except for the presence ofan addi-
tional methyl group on position five of the pyridazinone ring. It 
is three to five times more potent in vitro than CI-914 (11). We 
studied the hemodynamic response to this dmg in ten patients 
with severe congestive heart failure (34). Significant acute 
hemodynamic effects with a 35% increase in cardiac index 
(P < 0.002), a 35% decrease in pulmonary wedge pressure 
(P < 0.05), a 40% decrease in right atrial pressure (P < 0.05), 
and a 26% decrease in systemic vascular resistance (P < 0.05) 
occuned 15 minutes following intravenous CI-930. Similar ef-
fects were noted after oral CI-930, and the hemodynamic effects 
were sustained 12 to 18 hours after the oral dose. The sustained 
hemodynamic effects of this dmg are most likely a result of an 
active N-acetyl metabolite (35) rather than a direct action of the 
dmg because its plasma half-life was only 1.1 to 6.4 hours in the 
patients studied. The drug was well tolerated and has potential 
for treatment of heart failure. The role of this new class of ino-
tropic agents in the management of patients with heart failure 
needs to be defined. Although broadly classified as phospho-
diesterase inhibitors, these inotropic agents differ significantly 
from the classic PDE inhibitors in that they selectively inhibit 
the PDE isoenzyme III . 
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Several open label studies of the new agents claim superiority 
in symptom palliation for patients treated but inadequately con-
trolled with conventional dmg therapy (18,25). However, results 
of the only reported placebo-controlled trial with amrinone did 
not show significant improvement in exercise capacity or cardiac 
function (23,24). Evidently cardiac deterioration continues de-
spite the hemodynamic and clinical benefits during long-term 
therapy (15). Theoretical concems have been raised about the ra-
tionale for stimulating the failing myocardium (36). Whether 
these agents accelerate disease progression by exhausting the 
myocardial energy stores or adversely influence survival by ag-
gravating ventricular anhythmias is unclear The adverse effects 
may be related to an exacerbation of ischemia with use of these 
agents or may be due to the direct toxic effects of elevated cyclic 
AMP levels (37). These concerns are best addressed in careful. 
long-term, placebo-controlled trials foreach of these agents. 
These trials are cunently underway, and the results will soon be 
reported. These drugs are sdll investigational and need to be 
tested further as potendal therapeutic agents in the management 
of patients with heart failure. 
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